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Abstract 
Jiexin Deng：Understanding Paclitaxel / Pluronic F127 Nanocrystals Prepared by the 
Stabilization of Nanocrystal (SNC) Method 
 
(Under the direction of Dr. Feng Liu and Dr. Leaf Huang) 
 
 The objectives of this study were to understand the structure and stability of 
paclitaxel nanocrystals, as well as the biodistribution of nanocrystals after intravenous 
injection in mice.  The nanocrystal size increased after 2 h 37 oC incubation due to 
thermal induced aggregation.  The addition of more F127 surfactant further destabilized 
nanocrystals and led to a larger size increase concurrent with micelle formation.  
PTX/F127 nanocrystals (1/5 w/w) had little size increase upon dilution, indicating tight 
monomer surfactant absorption.  Nanocrystals of more F127 surfactant (1/20, 1/30 w/w) 
increased much in size upon dilution, suggesting low-affinity surfactant absorption with 
micelle formation in solution.  The re-nanonization after 37 oC incubation effectively 
inhibited crystal growth after 37 oC incubation again by disturbing the preferred crystal 
growth pattern of PTX.  The biodistribution of nanocrystals revealed that the majority of 
nanocrystals were quickly taken up by reticuloendothelial system and went to the liver 1 
h post injection.   
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Introduction 
 Paclitaxel (PTX), the first of a new class of microtubule stabilizing agents, has 
demonstrated significant antitumor activity in clinical trials against a broad range of solid 
tumors, including refractory ovarian cancer, metastatic breast cancer, non-small-cell lung 
cancer, AIDS-related Kaposi’s sarcoma1,2.  PTX is a highly hydrophobic diterpenoid 
pseudoalkaloid (of 853 Da3) with poor aqueous solubility of approximately 1 μg/mL4.  It 
is currently formulated as Taxol, a concentrated solution containing 6 mg PTX/mL of 
Cremophor EL (polyoxyl 35 castor oil) and dehydrated alcohol (1:1, v/v)2.  However, 
Cremophor EL component of the drug formulation is thought to be responsible for 
hypersensitivity reactions approaching some 25 to 30 percent of patients, since it can 
induce histamine release by mast and basophil cells5.  Therefore, novel formulations of 
paclitaxel alternative to the commercial ones are still highly desirable.  
 Attempts to solubilize poorly water soluble drugs such as paclitaxel using co-
solvents, in micelles, in liposomes, or with cyclodextrin has been of limited success.  An 
alternative formulation is nanosuspensions which are sub-micron colloidal dispersions of 
pure particles of drug that are stabilized by surfactants6.  Contrary to conventional 
approach of solubilizing insoluble drugs with excess amounts of co-solvents, 
nanosuspensions forgo the need of solubilization by stabilizing nano-sized drug crystals 
acceptable for pharmaceutical uses.   According to Noyes-Whitney and Ostwald-
Freundlich principles, homogeneous particle sizes of nanosuspension in nanometer range 
can lead to increased dissolution velocity and saturation solubility, thus increase in 
bioavailability7,8.  Nanosuspensions could be given in various routes of administrations 
such as oral9, parenteral10, ocular11, and pulmonary delivery12.  These nanosuspension 
studies by different routes of administration have revealed benefits such as increased rate 
and extent of absorption, increased bioavailability, reduced administration volumes, and 
increased resistance to hydrolysis and oxidation13.  Pharmacokinetic profiles of 
intravenous administration have shown the sustained release of nanosuspension by 
slowing diffusing out of monocyte phagocytic system following uptake for prolonged 
periods of time13. 
 One such nanosuspension formulation is PTX nanocrystals prepared using simple 
method of stabilization of nanocrystals (SNC) using a diblock copolymer Pluronic F127 
as the sole exipient14.  PTX is relatively complex organic drug having several solid 
structures such as crystal and amorphous, and the stabilized amorphous aggregate of PTX 
and F127 co-precipitation played an important role in SNC method.  The amorphous co-
precipitate provided the flexibility such that minimal energy and F127 were required in 
the nanoparticle forming process, and this resulted in simple preparation and high drug 
loading efficiency14.  The resulting nanoparticle formulation has low toxicity due to low 
PTX to F127 ratio, and the nanoparticle can bring higher amount of drug to cancer cells 
upon delivery.  In this study we would like to further understand the structure and 
stability of PTX/F127 nanocrystals, as well as the biodistribution of the nanocrystals after 
IV injection in mice.  X-ray powder diffractions were performed to evaluate the 
crystalline state of the nanocrystal samples.  The effects of increasing concentration of 
F127 surfactant on nanocrystal stability after 2 h 37 oC incubation were studied using 
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light scattering ZetaSizer.  TEM pictures of nanocrystal samples were taken to observe 
the morphology, crystal growth, and micelle formation in our samples.  F127 surfactant 
desorption from nanocrystals, and subsequent size increase, due to water dilution was 
studied with increasing surfactant concentration at room temperature and 37 oC.  The 
“Incubation-Sonication” procedure was used to make stable nanocrystals that resisted 
growth during 37 oC incubation.  Finally, the biodistribution of nanocrystals in mice 
plasma and organs 1 h post injection was evaluated. 
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Materials and Methods 
 Animals and Materials.  Female BALB/c mice (5 weeks old) were purchased 
from National Cancer Institute U.S. National Institute of Health (NCI).  Human lung 
cancer cell line, NCI-H460, was obtained from American Type Culture Collection.  All 
work performed on animals was in accordance with and permitted by the University of 
North Carolina Institutional Animal Care and Use Committee.  Paclitaxel (PTX) was 
bought from Lc Laboratories (Woburn, MA).  Pluronic F-127 (F127), Cremophor-EL, 
Butyl-4-hydroxybenzoate, and tert-butyl methyl ether (T-BME) were purchased from 
Sigma. 
 
 Preparation of the PTX samples.  The nanocrystals were prepared by the 
method of stabilization of nanocrystals (SNC).  Briefly, paclitaxel (PTX) and F127 were 
first dissolved in chloroform (in a glass tube) with a weight ratio of 1/5, 1/10, 1/20, or 
1/30 (PTX/F127) and then co-precipitated by evaporating the chloroform with a steady 
stream of nitrogen gas.  Traces of chloroform were then removed by keeping the samples 
under a vacuum with desiccators for 30 min.  Following 30 min of hydration (in double 
deionized water) and vortex, suspensions of the crystal were sonicated for 5 min by a 
bath-type sonicator (output 80 kc, 80 Watts) to form nanocrystals.  After hydration for 20 
min, the samples were sonicated for another 5 min.  For the physical mixture of 
PTX/F127, PTX and F127 were not co-dissolved in chloroform and were not co-
precipitated by evaporating the chloroform.  Only PTX was dissolved in chloroform, and 
the chloroform was evaporated with a stream of nitrogen, leaving PTX residues at the 
bottom of the tube.  Then aqueous F127 solutions of appropriate concentration were 
added to the residues of PTX to make the final weight ratio of 1/5 PTX/F127 w/w.  The 
mixture was then hydrated and sonicated in the same way as described for nanocrystals. 
 
 Transmission Electron Microscope (TEM).  Transmission electron microscopy 
(TEM) images of the resulting nanocrystals were acquired using a Phillips CM12 (FEI, 
Hillsboro, OR).  Freshly prepared nanoparticle samples (5 μl) were dropped onto a 300 
mesh carbon-coated copper grid (Ted Pella, Inc., Redding, CA) and allowed a short 
incubation (5 min) at room temperature. Grids were then stained with 1% uranyl acetate 
(40 μl) and wicked dry. All images were acquired at an accelerating voltage of 100 kV.  
Gatan DigitalMicrograph software was used to analyze the images. 
 
 Nanocrystal Size.  The distribution of cumulative particle size in the nanocrystal 
formulation was measured using ZetaSizer Nano-ZS of Malvern Instrument 
(Westborough, MA).  To study the effects of dilution on nanocrystal size, 1 ml of 
undiluted sample (143 μg PTX/mL H2O), 10 fold diluted sample, 50 fold diluted sample 
were placed in particle size measurement cuvette.  These samples were left standing at 
room temperature or incubated in 37 oC, and at various time points their particle size 
were measured. 
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 X-Ray Powder Diffraction.  The X-ray powder diffraction (XRPD) patterns for 
Paclitaxel samples were obtained with a Rigaku Multiflex diffractometer.  The X-ray 
source was Ni filtered CuK-alpha radiation (Wavelength 1.5418 A).  The X-ray tube was 
run at a power of 40 kV, 40 mA. The sample size was approximately 60 mg.  The 2θ 
range scanned was 7.5 to 60o at a rate of 0.25 deg 2θ/min at increments of 0.02o 2θ.  
 
H460 Cell Cytotoxicity Study.  The cytotoxicity of nanocrystals on NCI-H460 
human lung cancer cells were determined by MTT assay.  Briefly, H460 cells were 
seeded into 96-well plates at a concentration of 1×104 cells/well in a volume of 200 μl per 
well.  After 24 h, 20 μl of phosphate buffered saline (PBS) containing the nanocrystals 
were applied to H460 cells to make the final concentration to be 100 nM of PTX.  After 
43 hour of incubation, 20 μl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) solution (3.33 mg/ml) was added to cell medium in each 
well.  Following 2 hour of incubation with MTT, medium were removed and 100 μl of 
dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals.  The 
absorbance values were then measured on a microplate reader (Hidex Plate Chameleon, 
Turku, Finland) at the wavelength of 570 nm.  Cell viability was calculated using the 
following formula: %viability = (A570 nm for the treated cells / A570 nm for the control 
cells) × 100%, where A570 nm is the absorbance. 
  
 Biodistribution of Paclitaxel Formulations.  Biodistribution study of paclitaxel 
was performed on Balb/C mice, and the animals were kept in the animal facility and had 
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free access to food and water.  For administration, nanocrystal (1/5 w/w PTX/F127) 
formulations were suspended in certain volumes of PBS (pH 7.4) in order to obtain the 
required concentration.  The different formulations were injected through the tail vein at 
the paclitaxel dose of 20 mg/kg mouse, and each group consisted of 5 animals.  One hour 
after injection, blood and organs (liver, lung, spleen, kidney) were collected.  Blood was 
obtained from the retro orbital plexus, and plasma was obtained by immediately 
centrifuging blood samples with EDTA at 7000 g for 5 min.  Harvested tissues were 
stored at -20 oC until analyzed for paclitaxel by HPLC. 
  
 HPLC Analysis of Paclitaxel.  HPLC method was used for the analysis of 
paclitaxel concentration in all samples.  For plasma samples, 200 μL of plasma was 
spiked with 10 μL of butyl-4-hydroxybenzoate (50 μg/mL) as internal standard.  For 
paclitaxel plasma standard curve 20 μL of paclitaxel of appropriate concentrations along 
with the internal standards were dissolved in the plasma samples.  After addition of 100 
μl of acetonitrile, the plasma samples were then extracted with 2 mL of tert-butyl methyl 
ether (T-BME) with vigorous mixing for 5 minutes.  After centrifugation at 3000 rpm for 
5 minutes, the organic phase was collected.  The extraction procedure was repeated with 
2 mL of T-BME, and total organic phase was combined and dried under nitrogen gas.  
The residue was then dissolved in 100 μL of the mobile phase, 45% acetonitrile / water.  
The solution was centrifuged for 5 min at 3000 rpm, and 50 μL of the supernatant was 
injected into the HPLC system for analysis. 
 For tissue organs, the tissue samples (liver, spleen, lung, kidney) were 
homogenized with 1 mL of water Bovine Serum Albumin (BSA) solution, containing 4% 
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(w/v) bovine serum albumin, using a tissue homogenizer for 5 min at 4 oC.  The tissue 
homogenate (1.0 mL) was spiked with 10 μL of internal standard (Butyl-4-
hydroxybenzoate, 50 μg/mL).  For paclitaxel organs standard curve 20 μL of paclitaxel of 
appropriate concentrations along with the internal standards were dissolved in the organ 
samples.  The samples were then extracted twice with 2 mL of T-BME as described for 
the plasma sample.  The T-BME fractions were then combined and were dried under 
nitrogen gas.  The residue was dissolved with 100 μL of mobile phase, 45% Acetonitrile / 
Water, and was mixed for 5 minutes.  The solution was centrifuged at 3000 rpm for 5 
min, and 10 μL of the supernatant was injected into the HPLC system for analysis.  The 
HPLC system was performed at a flow rate of 1.0 ml/min at 228 nm with a UV detector, 
using a 25mm × 4.6 I.D. mm reverse phase Analytical column of Axxiom 
Chromatography (Moorpark, CA). 
  
Statistical Analysis.  All statistical analyses were performed by a two-tailed 
student t-test.  Data were considered statistically significant when the P value was less 
than 0.05. 
 
8 
 
  
Results 
A.  Understanding the Structure and Stability of PTX / F127 Nanocrystals 
 
1.  Crystalline Structure Identification of Nanocrystals  
 
 Although nanocrystals could be observed under TEM, the crystalline structure of 
nanocrystals was never evaluated.  Therefore X-ray powder diffraction analysis was 
carried out for nanocrystals (PTX/F127 1/5 w/w) as well as physical mixture in 
comparison with pure PTX and F127.   Figure 1 shows the X-ray diffraction peaks for 
pure paclitaxel, pure F127, nanocrystals, and PTX/F127 physical mixture.  As shown in 
figure 1, the X-ray diffraction pattern of the nanocrystals showed the combined peaks of 
both of the pure components (paclitaxel and F127).  The F127 peaks were much more 
prominent than the peaks of paclitaxel near the base line at 2θ of 10o to 15o, this is 
because F127 were present in larger weight ratio (1/5) in the formulation.  The X-ray 
powder diffraction confirmed that in nanocrystal formulation both Paclitaxel and F127 
components retained their native crystalline structure.  X-ray diffraction peaks for 
physical mixture were also shown in figure 1c.  The diffraction peaks for nanocrystal and 
PTX/F127 physical mixture were highly similar.  Table 1 is a summary of the major X-
ray diffraction peaks for each sample, and the nanocrystals and physical mixture had peak 
characteristics of PTX and F127.   
 From x-ray diffraction pattern, nanocrystals and the PTX/F127 physical mixture 
were highly similar in composition and crystalline structure.  However, as could be 
expected the crystal formation in nanocrystal samples and the physical mixture were very 
different.   As shown in figure 2b, the crystal growth of PTX alone with out surfactant 
was vastly different than that of nanocrystal in shape and pattern.  Nanocrystals were rod-
shaped structures stabilized by F127 surfactant on the surface; on the other hand, PTX 
alone formed small trunks of irregular crystals and aggregated with each other.  Figure 2c 
shows the aggregate formed in PTX/F127 physical mixture.  While there were 
resemblances of rod-shaped crystals, these individual crystals collapsed and aggregated 
with each other forming a mass.  Due to the lack of the co-solvation (in chloroform) and 
co-precipitation step, F127 surfactant in physical mixture could not be adequately coated 
on the surface of nanocrystals to prevent the aggregation. 
 
2.  Effects of Increasing Surfactant on Thermal Stability of Nanocrystals  
 
 It is known that the aggregation efficiency of hydrophobic particles would be 
enhanced at higher temperatures15.  As shown in figure 3 this is also true for our 
nanocrystals, and after 37 oC incubation for 2 hours longer crystals were formed despite 
the fact that nanocrystals were stabilized by F127 surfactant.  The size as measured by the 
ZetaSizer went from 176 nm to 258 nm after 2 hour incubation at 37 oC.  Therefore, to 
attempt to further protect the nanocrystals, higher amounts of F127 surfactant were used 
to prepare PTX/F127 nanocrystals of ratios 1/10, 1/20, and 1/30 w/w.  On the contrary, as 
shown in Table 2 the measured size after 37 oC incubation increases with higher amount 
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of F127 surfactant used.  The measured size for PTX/F127 (1/5 w/w) after 37 oC 
incubation was 258 nm, but for PTX/F127 (1/20 w/w) and (1/30 w/w) the sizes were 359 
and 441 nm respectively after 37 oC incubation.   
Due to the inaccuracies of measurement by ZetaSizer for rod-shaped crystals, 
manual measurements were performed for the TEM pictures, and the results were shown 
in Table 3.  At least 20 crystals of various field-views were measured for each sample, 
and the average values with standard deviations were given.  For nanocrystals prepared 
with 1/5 w/w of F127, the sizes both before and after 37 oC were statistically smaller than 
the sizes of crystals with higher concentration of F127.  The manual measuring in TEM 
confirmed the trend in size change measured by the ZetaSizer.  Adding more F127 
surfactant to the preparation did not help to increase the stability of nanocrystals during 2 
h 37 oC incubation.    
 In order to observe the effects of increasing concentrations of F127 on the 
cytotoxicity of nanocrystals, PTX nanocrystals with different concentrations of F127 
surfactants (1/10, 1/20, 1/30 w/w) were prepared and were applied to NCI-H460 cells.  
As shown in figure 4, F127 alone at all concentrations (1/10, 1/20, 1/30 w/w) did not 
cause significant cytotoxicity.  Also, the increase in F127 concentrations in nanocrystal 
formulations did not have significant effects on cell viability, as the nanocrystals 
treatment groups all had about 45% cell viability regardless of the concentration of F127.  
Therefore increasing F127 concentrations did not alter the cytotoxic effects of 
nanocrystals on NCI-H460 cells. 
 The reason why increasing amount of F127 did not help to further stabilize 
nanocrystals during 2 h 37 oC incubation became clear in figure 5, which showed that the 
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formation of micelles was evident at higher concentration of F127 surfactant.  The CMC 
of Pluronic F127 at 25 oC is 7.19 × 10-5 M27.  The concentration of F127 in nanocrystals 
prepared with 1/5 w/w of PTX/F127 is below the CMC of F127.  However, for 1/10, 1/20, 
and 1/30 of PTX/F127, the concentration of surfactant goes beyond the CMC.  Instead of 
forming a thicker coating layer, the additional F127 formed micelles that competed for 
nanocrystal surface adsorption.  Unimers of F127 surfactant bound the surface of 
nanocrystals with high affinity due to hydrophobic interactions.  As the concentration of 
F127 increased however, surface monomers interacted with each other, forming “hemi-
micelles” on the surface of nanocrystals that bound with lower affinity than monomers.  
These lower affinity surfactant could easily be competed off the nanocrystal surface.  So 
this could actually mean less surface adsorption due to competition by micelles as more 
F127 surfactant was added to the sample, and less surface adsorption means less stability 
for nanocrystals during 2 h 37 oC incubation. 
 
3.  The Effects of Dilution on Surfactant Adsorption and Nanocrystal Stability 
 
 Upon IV injection nanocrystals would be diluted many folds in the blood stream, 
therefore, it would be important to understand the effects of water dilution on surfactant 
adsorption and nanocrystal stability.  As shown in Figure 6, our nanocrystals are in a 
meta-stable state stabilized by surface adsorbed F127 surfactant.  At low concentration of 
F127 (1/5 w/w PTX/F127) monomers bind with high affinity.  At high concentration of 
F127, monomers aggregated and bind to surface with low affinity; there is also micelle 
formation competing for surface adsorption.  In this experiment, nanocrystal samples 
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were diluted 10 fold or 50 fold to attempt to draw the adsorbed surfactant layer into free 
form.  By doing so, it is expected that the particle size of PTX nanocrystals would 
increase upon dilution if surfactant does indeed leave.  ZetaSizer measures the size of 
particles using light scattering from only one angle rather than multiple angles, and there 
would be measurement inaccuracies for our long rod-shaped PTX crystals.  However, the 
ZetaSizer does give a cumulative measurement of total particle size in solution and is 
more than capable of giving an idea of the level of crystal aggregation.   
As seen in figure 7a, PTX nanocrystals prepared with 1:5 w/w of F127 increased 
a little in size as time went on however, size increase upon dilution was not observed.  As 
shown by 7b to 7d, the crystal size of nanocrystals formulations containing higher 
amounts of F127 (1/20, 1/30 w/w) drastically increased upon dilution.  In TEM pictures 
of figure 8, micelle formations were evident in undiluted samples with higher F127 
concentration at the end of the dilution-size experiment.  These data indicate that the 
affinity of surfactant binding to the surface of nanocrystals at low concentration of 
surfactant (1/5 w/w) was not the same as that of nanocrystals with high concentration of 
surfactant (1/20, 1/30 w/w).  At low concentration of F127 (1/5 w/w), no micelles were 
observed in TEM, and it is likely that monomers bound to nanocrystals with high affinity, 
and dilution could not pull the surfactant off the surface.  At higher concentration of F127 
(1/20, 1/30 w/w), micelles started to form that would compete for surface adsorption of 
F127 (Figure 9).  Also, the size increase upon dilution of the nanocrystals of 1/20 and 
1/30 PTX/F127 suggests that the surfactant bound with lower affinity, coming off easily 
upon dilution.  It is likely that as F127 concentration increased, monomers started to lose 
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the high affinity to surface of nanocrystals and would instead interact more with each 
other. 
 The Critical Micelle Concentration (CMC) of F127 would decrease drastically 
from 0.3 wt % at room temperature to 0.025 wt % at 37 oC16.  Therefore, it would be 
interesting to find out whether the nanocrystal size increases upon dilution at 37 oC where 
micelle formation would be enhanced.  As shown in figure 10, for PTX/F127 1:5 w/w the 
nanocrystal size indeed increased upon dilution at 37 oC.  This suggests that monomers 
on the surface of nanocrystals started to aggregate at higher temperature and was drawn 
to leave the crystal surface upon dilution, making the crystal prone to aggregate.  This 
size increase upon dilution for nanocrystals of 1/5 w/w PTX/F127 was not observed at 
room temperature, where no micelles were formed.       
 
4.  Increase of Nanocrystal Stability by Re-nanonization 
 
 The crystal growth of nanocrystals after 37 oC incubation presents storage 
problems, because long crystals could also form at room temperature after preparation or 
reconstitution due to Ostwald ripening17,18.  To solve this problem, sonication for 15 
minutes was used to break down the longer crystals after incubation at 37 oC, resulting in 
smaller nanocrystals again, and the sonicated nanocrystals were then incubated at 37 oC 
for 2 hours again to see if the incubation would cause regrowth into longer crystals 
(Figure 11).  As shown by Figure 12, the “incubation-sonication” procedure effectively 
prevented the growth of nanocrystals at 37 oC incubation and provided a much better 
thermal stability for nanocrystals.  It is assumed that the crystal growth pattern would be 
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disturbed by sonicating large nanocrystals after 37 oC incubation, and it would be 
difficult to regrow crystals into longer needle-like crystals, thus providing better stability.   
To confirm, manual measurements were performed in TEM pictures, and the 
results with standard deviations were given in Table 4.  According to the measurements, 
the second time 37 oC incubation did not induce statistically significant increase in length 
after the “incubation-sonication” procedure.  Rather the increase in width in sample C 
was significant.  This showed that the “incubation-sonication” procedure made it difficult 
for crystals to regrow in length, which is the preferred growth pattern for PTX crystals.  
Thus, this procedure provided overall inhibition of crystal growth and better crystal 
stability. 
The cytotoxic effects of nanocrystal on NCI-H460 cells after the “Sonication-
Incubation” procedure were studied.  As shown in figure 13, the different treatments of 
10 μM PTX were 1) before 2 hr 37 oC incubation, 2) after 2 hr 37 oC incubation, 3) after 
2 hr 37 oC incubation then sonication, 4) after 2 hr 37 oC incubation then sonication then 
2 hr 37 oC incubation again.  The different preparative procedures did not cause 
significant differences in cytotoxicity, and the cell viability were 40 to 45% across all 
treatment groups.  The crystalline state of nanocrystals after “Sonication-Incubation” 
procedure were also evaluated using X-ray Powder Diffraction analysis.  It was found 
that the nanocrystal crystallinity was unaltered by procedures such as 37 oC incubation 
and sonication (Table 5). 
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B.  Biodistribution of Nanocrystals  
 
1.  The Difference in Extraction Efficiency of Taxol® and Nanocrystal 
 
 PTX samples were extracted from plasma and tissue samples and were 
subsequently analyzed by HPLC in the biodistribution study.  To investigate whether 
there was extraction  efficiency differences between the two PTX formulations, 600 μL 
of blood was spiked with 50 μg of paclitaxel formulations (Taxol® and nanocrystals), 
then the blood was centrifuged at 7000 g for 5 minutes to separate the plasma and blood 
precipitate.  200 μL of plasma was then extracted with tert-butyl methyl ether (TBME) 
for analysis by HPLC.  As shown by the HPLC results in Table 6A, there were 
differences in extraction for the two formulations (i.e. Taxol® and nanocrystals).  For the 
same amount of paclitaxel spiked in the blood, the HPLC ratio (PTX/Internal STD) of 
Taxol® formulation is 2.86 times larger than that of the nanocrystal.  To confirm that this 
difference is indeed due to extraction differences and not due to formulation itself, 10 μg 
of paclitaxel in plasma of both formulations were directly injected into HPLC, and 
similar HPLC ratio were obtained as shown in Table 6B (61.87 for Taxol®  and 58.13 for 
nanocrystal).  The nanocrystals extraction by tert-butyl methyl ether (TBME) was lower 
compared with that of Taxol®.  To resolve the differences in extraction between the two 
formulations, 100 μL of acetonitrile was added to plasma samples to dissolve the 
nanocrystals prior to extraction by TBME (Figure 14).  As shown in Table 6C, for the 
same amount of paclitaxel spiked in plasma, the HPLC ratios were similar for Taxol® and 
nanocrystal after the addition of acetonitrile prior to extraction by TBME.   
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 2.  Difference in Extraction Recovery of Plasma and Organs 
 
 In order to construct a paclitaxel in plasma standard curve, various amounts of 
paclitaxel were dissolved in plasma, and the internal standard (Butyl-4-hydroxybenzoate) 
was fixed in all plasma samples.  After the addition of 100 μL of acetonitrile, the plasma 
samples containing paclitaxel and internal standard were extracted using tert-butyl methyl 
ether (T-BME) twice, and the organic phase was dried with a stream of nitrogen gas.  The 
residue was then reconstituted with 100 μL of mobile phase, and 50 μL of the 
reconstituted samples were then injected into HPLC for analysis.  The resulting paclitaxel 
plasma and organs standard curves were shown in figure 15, and the liver PTX standard 
curve was significantly differently from that of the other organs.   
 
3.  PTX Nanocrystal Biodistribution Study 
 
 The PTX nanocrystal biodistribution in mice plasma and organs 1 h post injection 
was displayed in figure 16.  The plasma concentration of nanocrystal consists of only 
12.63% of recovered dose, and the majority of the nanocrystal went to the liver (65.85%) 
due to rapid reticuloendothelial system (RES) uptake.  It seems that F127 surfactant on 
the surface of nanocrystals could prevent aggregation, yet the surfactants were unable to 
protect the nanocrystals from RES uptake.  The nanocrystals formed by F127 Pluronic 
formulation were of rod-shaped and of <150 nm in length.  It was hoped that the small 
rod shaped nanocrystals could escape reticuloendothelial system (RES) uptake.  Despite 
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this property, the biodistribution data shown indicated that the F127 nanocrystals formed 
were still largely taken up by the RES system and went into liver.   
 
 
 
18 
 
  
Discussion 
 Nanosuspensions are useful dosage forms for the formulation of water-insoluble 
drugs13,19.  Techniques such as high-pressure homogenization and wet milling are often 
used to produce nanosuspensions of small size suitable for pharmaceutical uses, these 
nanosuspensions are stabilized by surfactant such as Pluronics polymers for storage 
purposes to prevent aggregation20,21.  Studies have demonstrated that stable 
nanosuspensions of sparingly water-soluble drugs was comparable or improved over the 
response elicited by the conventional formulations; dosages could be increased without 
incidence of acute toxicity, abnormal weight loss, or organ pathology14,21.  Currently five 
products are on the market by the approval of FDA since the year 2000, all intended for 
oral delivery; all five products are based on top-down approaches such as media milling 
and high-pressure homogenization22.  PTX/F127 nanocrystal is a nanosuspension 
formulation of PTX developed in our lab using stabilization of nanocrystals (SNC) 
method, and the objectives of this study were to further understand the structure and 
stability of the nanocrystals, as well as the biodistribution of the nanocrystals 1 h post 
injection in vivo. 
The state of crystallinity of the nanocrystals was evaluated using X-ray powder 
diffraction.  F127 is a semicrystalline polymer, with the crystalline phase consisting of 
PEO layers and amorphous layers formed by PPO and PEO23.  Nanocrystals, as well as 
PTX/F127 physical mixture, has the diffraction pattern consisting of both pure PTX and 
F127 (figure 1), showing that the crystallinity of nanocrystals were unaltered by the 
preparation and lyophilization process.  Because the PTX/F127 physical mixture and 
nanocrystals had very similar XRD patterns, TEM pictures were taken to observe 
compare the crystal growth morphology of physical mixture and nanocrystals (Figure 2).  
The pure PTX crystals were highly irregular in shape that aggregated with each other.  
While the PTX/F127 physical mixture had semblance of rod-shaped crystals, the crystals 
aggregated with each other into a mass because the F127 were unable to adequately 
stabilize the crystals.  This shows that the co-solvation in chloroform and subsequent co-
precipitation were important steps in preparing stable nanocrystals, without these steps, 
the crystals formed would collapse into a mass. 
Hydrophobic interactions are negative entropic processes, therefore, the higher 
the temperature of the suspension, the more thermodynamically unfavorable the system 
becomes; in hydrophobic suspensions, the tendency of aggregation is enhanced at higher 
temperature15.  Our nanocrystals stabilized by F127 surfactant increased in size upon 2 h 
incubation at 37 oC, becoming crystals of great length (figure 3).  It has been reported that 
further increase in surfactant in nanosuspensions could afford thicker coating layer to the 
nanocrystals, thus providing better long-term stability17,24.  Therefore, in our study 
nanocrystals with increasing F127 surfactant were prepared (1/10, 1/20, 1/30 w/w 
PTX/F127).  It was hoped that the increase in F127 could afford better stability against 
aggregation from 37 oC incubation.  On the contrary however, nanocrystals with higher 
concentration of F127 surfactant increased even more in size after 2 h 37 oC incubation 
(Table 2).  This trend was confirmed by manually measuring the nanocrystals in each 
TEM field-view (Table 3).  The reason for this trend became clear from TEM (Figure 5), 
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instead of forming a thicker layer on the nanocrystals surface, micelles began to form in 
solution at higher concentration of F127.  The CMC of Pluronic F127 at 25 oC is 7.19 × 
10-5 M27.  The concentration of F127 in nanocrystals prepared with 1/5 w/w of PTX/F127 
is below the CMC of F127.  However, for 1/10, 1/20, and 1/30 of PTX/F127, the 
concentration of surfactant goes beyond the CMC.  After the attainment of the CMC, the 
micelles began to compete for surface adsorption so that the total adsorption at the 
interface begins to decrease as the micelles become more numerous25.  Another study on 
the adsorption of Pluronic polymers on the adsorption of DDS-glass by radiolabelling 
also confirmed this effect26.  Thus, the higher F127 surfactant concentration could 
actually mean less surfactant adsorption, which would further destabilize the nanocrystals 
during the 2 h 37 oC incubation, thus contributing to a larger size increase.  Croy et al. 
studied the effects of Pluronic polymers on the aggregation state of poorly soluble 
nystatin.  They found that nystatin could partition into pluronic micelles and the largest 
contributing factor to the solubilization of nystatin was the number and size of the 
micelles formed27.  However in our case PTX nanocrystals were stabilized by surface 
adsorption of F127 surfactant, and the formation of micelles would compete with F127 
surface adsorption—thus destabilizing the nanocrystals. 
The effects of dilution on size increase of nanocrystals prepared with varying 
amounts of F127 (1/5, 1/10, 1/20, 1/30 w/w) were studied.  The nanocrystals were in a 
meta-stable state with free surfactant in solution and adsorbed surfactant for stabilization.  
By dilution it is hoped that the equilibrium would be shifted such that the adsorbed 
surfactant would leave the nanocrystals and go into the free form.  If the surfactant does 
indeed leave, the crystal size increase would be detected.  It was found that for 
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nanocrystals of 1/5 w/w PTX/F127, the dilution had no effect on size increase; however, 
nanocrystals prepared with higher amount of F127 (1/10, 1/20, 1/30 w/w) increased much 
in size upon dilution (Figure 7).  The TEM of undiluted samples at the end of the 
experiment (Figure 8) revealed micelle formation in nanocrystals samples with higher 
concentration of surfactant (1/20, 1/30 w/w PTX/F127).   
One study by Lin et al. using dynamic light scattering (DLS) and small-angle 
neutron scattering (SANS) found that below CMC PPO of Pluronic F127 preferred 
hydrophobic Carbon Black (CB) particle surface to water, but above CMC Pluronic F127 
preferred to associate with each other and had decreased affinity to CB surface28.  Below 
CMC monolayer of F127 monomers bound to CB surface with high affinity, above CMC 
adsorbed layer thickness measured by DLS, as well as structure determined by SANS, 
suggested that the adsorbed layer was in the form of micelles28.  The observation that at 
higher bulk surfactant concentration, micelles, or monomer aggregates “hemi-micelles”, 
bound to hydrophobic surface with lower affinity is also confirmed by Amiji using 
radiolabelling methods26.  This is in line with our observation that at higher F127 
concentration surface surfactants readily leave upon dilution, making the crystals increase 
in size.  At higher F127 concentration where micellization occurs, F127 monomers on the 
surface aggregated with each other and consequently bound the surface with lower 
affinity.   
It is known that the CMC of Pluronic F127 decreases strongly with increasing 
temperature, from 0.3 wt % at room temperature to 0.025 wt % at 37 oC16.  At higher 
temperatures the surfactant adsorption is inhibited more than micellization, meaning that 
micellization will out-compete surface adsorption29.  At 37 oC nanocrystals of 1/5 
22 
 
PTX/F127 increased in size upon dilution concurrent with micelle formation (Figure 10), 
whereas at room temperature the same nanocrystals did not increase in sizes.  This 
experiment thus showed again that in samples with micelle formation either because of 
high F127 concentration or induced by higher temperature, surface surfactant aggregated 
and bound the nanocrystals with lower affinity; the surfactant readily desorbed upon 
dilution, destabilizing nanocrystals and causing size increase. 
 The size increase of nanocrystals due to thermal induced aggregation at 37 oC 
incubation or Ostwald ripening at room temperature poses storage problems and could be 
undesirable.  This negates important advantages of nanosuspensions, such as the increase 
in saturation solubility and increase in dissolution rate of compound30.  Nanosuspensions 
have shown increased antitumor efficacy by taking advantage of the Enhanced 
Permeability and Retention (EPR) effect during its prolonged retention time31.  It would 
be difficult for large crystals to take advantage of the EPR effect.  Therefore the 
“Incubation-Sonication” procedure was used to provide better stability of the 
nanocrystals.  After the crystal size increased after the 2 h 37 oC incubation, sonication 
was used to break down the samples into smaller nanocrystals.  After incubating at 37 oC 
for 2 hours, it was found that the “Incubation-Sonication” procedure (figure 11) 
effectively prevented the regrowth into longer crystals (figure 12).  Closer examination 
by manual measuring in TEM revealed that the “Incubation-Sonication” procedure 
prevented the regrowth in length of the crystals; however, the growth in width of the 
crystals was statistically significant (Table 4).  The growth in width was less favored by 
the nanocrystals.  Therefore, the “Incubation-Sonication” procedure disturbed the growth 
pattern of the nanocrystals, thus providing better stability.  
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HPLC was used to analyze PTX in biodistribution studies, and it was found that 
there were extraction differences by tert-butyl methyl ether.  The ratio of PTX to internal 
standard ratio was 2.86 times larger for Taxol® than for nanocrystals (Table 6A).  As 
opposed to using excess co-solvents such as Cremophor EL to dissolve PTX, nanocrystal 
formulation is in a dense, solid state that has the property of higher mass per volume13.  
This could be the reason PTX extraction efficiency by TBME is lower for nanocrystals 
than for Taxol®, and to resolve the difference, acetonitrile had to be added as a co-solvent 
to dissolve the nanocrystals prior to extraction (figure 14).  PTX standard curves were 
constructed for plasma and organs, and it was found that the liver standard curve was 
significantly different from the others (Figure 15).   
The biodistribution of nanocrystals 1 h post intravenous injection revealed that 
majority of nanocrystals (65.86%) were quickly taken up by the RES system and went to 
the liver (Figure 16).  Several pharmacokinetic profiles have been reported for 
nanosuspensions after intravenous injection.  If the particles dissolve in the blood readily, 
both the pharmacokinetics and tissue distribution will be equivalent to those for the 
solution formulations32,33.  However, there is evidence that our nanocrystals are slow-
dissolving after injection into the blood stream.  Previous studies have shown that slow 
dissolving nanocrystals were taken up by the phagocytic cells of the mononuclear 
phagocyte system (MPS), primarily the Kupffer cells in the liver, spleen, and lungs34,35.  
The drug particles could dissolve in the reduced pH environment of the 
phagolysosomes36 and slowly diffuse out of the MPS cells based on their lipophilic 
character13.  This effect will result in a pharmacokinetic profile with significantly reduced 
Cmax, but quite prolonged t1/2, and this trend has been observed for nanosuspensions by 
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many studies20,37.  This can be very advantageous for certain drug classes, for which 
toxicity is mediated by peak plasma values, but for which efficacy is driven by AUC, as 
in the case of triazole antifungals38. 
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Conclusion 
 In conclusion, the crystalline structure of PTX nanocrystals was unaltered from 
that of pure PTX based on X-ray Powder Diffraction analysis.  The nanocrystal size 
increased after 2 h 37 oC incubation due to thermal induced aggregation, and more F127 
surfactant further destabilized nanocrystals and led to a large size increase concurrent 
with micelle formation.  Cytotoxicity on H460 cells indicate that increased F127 did not 
affect the cytotoxicty of the nanocrystals.  PTX/F127 nanocrystals (1/5 w/w) had little 
size increase upon dilution, and nanocrystals of increasing F127 surfactant (1/20, 1/30 
w/w) increased much in size upon dilution.  At 37 oC where micellization is enhanced, 
even PTX/F127 nanocrystals (1/5 w/w) increased in size upon dilution.  The “Incubation-
Sonication” procedure effectively inhibited crystal growth after 37 oC by disturbing the 
preferred crystal growth pattern of PTX.  The cytotoxicity and crystalline structure of 
nanocrystals were unaltered after “incubation-sonication” procedure.  Finally, the 
biodistribtuion of nanocrystals revealed that majority of nanocrystals were quickly taken 
up by the reticuloendothelial system and went to the liver 1 h post injection. 
  
 
Table 1.  X-Ray Powder Diffraction Peaks and Corresponding d spacings for pure PTX, 
pure F127, nanocrystal, and PTX/F127 physical mixture. 
 
2θ 
Angle 
d spacing 
(Angstrom) 
Pure PTX Pure F127 Nanocrystal Physical 
Mixture 
9.8 9.02 Present 
(weak) 
 Present Present 
11 8.04 Present  Present 
(faint) 
Present 
(weak) 
12 7.38 Present  Present Present 
13.5 6.56 Present  Present Present 
19.5 4.55  Present  Present Present 
23.7 3.75  Present Present Present 
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Table 2.   Nanocrystal size increase after 37 oC incubation for 2 hours.  Nanocrystals 
prepared with various amounts of F127 were measured for their sizes before and after 37 
oC incubation. 
 
 
 Measured Size (nm) 
Before 37 oC Incubation
Measured Size (nm) 
After 37 oC Incubation 
PTX/F127 (1/5 w/w) 176 258 
PTX/F127 (1/10 w/w) 187 303 
PTX/F127 (1/20 w/w) 158 359 
PTX/F127 (1/30 w/w) 181 441 
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Table 3.  Size of nanocrystals prepared with various amounts of F127 determined by 
manual measuring in TEM.  At least 20 crystals were measured for each sample.  **For 
the length of nanocrystal, P < 0.05 when compared to either PTX (1/10), (1/20), or (1/30). 
 
 
 
 Measured Size (nm) 
Before 37 oC incubation 
Measured Size (nm) 
After 37 oC incubation 
PTX/F127 
(1/5 w/w) 
37 × 160** 
(±7 × ±47) 
53 × 660** 
(±18 × ±318) 
PTX/F127 
(1/10 w/w) 
39 × 297 
(±10 × ±113) 
57 × 971 
(±14 × ±324) 
PTX/F127 
(1/20 w/w) 
45 × 322 
(±11 × ±82) 
47 × 1273 
(±10 × ±652) 
PTX/F127 
(1/30 w/w) 
37 × 344 
(±10 × ±149) ------ 
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Table 4.   The size of nanocrystals prepared by manual measurements in TEM.  Samples 
are PTX/F127 nanocrystals before 37 oC incubation (Sample A), nanocrystals after 37 oC 
incubation then sonication (Sample B), nanocrystals after 37 oC incubation, sonication, 
then 37 oC incubation again (Sample C).  The increases in length of sample C was not 
statistically significant compared to A or B.  *For the width of nanocrystals, p < 0.05 
compared to either Sample A and B. 
 
 Measured Size (nm) 
Sample A 
PTX/F127 Before 37 oC 
(1/5 w/w) 
37 × 160 
(±7 × ±47) 
Sample B 
PTX/F127 
37 oC – Sonication 
(1/5 w/w) 
63 × 177 
(±7 × ±46) 
Sample C 
PTX/F127 
37 C – Sonication – 37 oC 
(1/5 w/w) 
73* × 185 
(±12 × ±68) 
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Table 5.  X-ray Powder Diffraction Analysis of nanocrystals after the “Sonication-
Incubation” procedure.  The crystalline structure were unaltered for (1) nanocrystals after 
37 oC incubation and (2) nanocrystals after 37 oC incubation, then sonication, then 
incubated at 37 oC for 2 h again. 
 
 
2θ 
Angle 
d spacing 
(Angstrom) 
Pure 
PTX 
Pure 
F127 
Nanocrystal
37 oC 
Incubation 
Nanocrystal 
37 oC 
Incubation 
Sonication 
37 oC 
Incubation 
9.8 9.02 Present (weak)  Present Present 
11 8.04 Present  Present Present 
12 7.38 Present  Present Present 
13.5 6.56 Present  Present Present 
19.5 4.55  Present Present Present 
23.7 3.75  Present Present Present 
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Table 6.  (A) HPLC plasma results of 600 μL of blood spiked with 50 μg of paclitaxel 
extracted with TBME without the addition of acetonitrile prior to extraction  (B)  HPLC 
results of 10 μg of paclitaxel by direct injection  (C)  HPLC plasma results of 600 μL of 
blood spiked with 10 μg of paclitaxel extracted with TBME with the addition of 
acetonitrile prior to extraction. 
 
  A) 
Name  Retention Time  Area  Ratio  
Plasma Taxol® 22.4 11956375 (PTX/Int) 
Internal Standard  12.8 47329.08 252.6 
Name  Retention Time  Area  Ratio 
Plasma Nanocrystal  22.5 4108067 (PTX/Int) 
Internal Standard  12.9 46524.07 88.3 
 
B) 
Name  Retention Time  Area  Ratio  
Internal Standard  12.1 54806.8 (PTX/Int) 
Taxol® (10 μg) 
Direct Injection  18.5 3390698 61.9 
Name  Retention Time  Area  Ratio  
Internal Standard  12.1 55726.55 (PTX/Int) 
Nanocrystal (10 μg) 
Direct Injection  18.5 3239422 58.1 
 
C) 
Name  Retention Time  Area  Ratio  
Internal Standard  12.2 49270.75 (PTX/Int) 
Plasma Taxol®  
(with Acetonitrile)  18.6 1478042 30.0 
Name  Retention Time  Area  Ratio  
Internal Standard  12.3 42690.28 (PTX/Int) 
Plasma Nanocrystal 
(with Acetonitrile)  18.8 1175104 27.5 
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Figure 1.  X-Ray Powder Diffraction Peaks for A) pure paclitaxel B) pure F127 C) 
nanocrystals and physical mixture of PTX and F127. 
 
 
 
A) 
 
B) 
 
C) 
33 
 
Figure 2.  TEM pictures of A) PTX/F127 nanocrystals (1/5 w/w)  B) PTX crystal without 
addition of F127 surfactant.  C) Physical mixture of PTX and F127 surfactant.  
 
 
  
A) 
   
B) 
   
C) 
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Figure 3.   TEM pictures of nanocrystals for thermal stability studies. A) Nanocrystals 
before 37 oC incubation. Measured size using ZetaSizer 176 nm  B) Longer crystals 
formed by incubation at 37 oC for 2 hours. Measured size using ZetaSizer 258 nm.   
 
 
   
A) 
 
   
B) 
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Figure 4.  Effects of Increasing F127 Concentrations on Nanocrystal Cytotoxicity.  
Nanocrystals of 1/10, 1/20, 1/30 w/w PTX/F127 were prepared and applied to H460 cells.  
F127 of various concentrations without PTX were also tested.  Each data represents the 
mean ± standard deviation (n = 6). 
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Figure 5.  TEM of nanocrystals of A) PTX/F127 (1/10 w/w) and B) PTX/F127 (1/20 
w/w).  The white spherical structures in the background are micelles formed at high 
concentration of F127. 
 
 
     
A) 
 
  
B) 
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Figure 6. Illustration of nanocrystal stabilized by F127 at either low (1/5 w/w PTX/F127) 
or high concentration (1/20, 1/30 w/w PTX/F127).  For nanocrystals prepared with low 
concentration of F127, monomers bound with high affinity.  As more F127 was added, 
there was micelles formation in solution and formation of surfactant aggregates (hemi-
micelles) on nanocrystal surface.  Micelles could also compete for surface adsorbed F127 
surfactants. 
 
 
 
Surfactant binds 
With High Affinity
More F127 Added
Above CMC
• Surfactant binds With low Affinity
• Micelles competing for surface adsorption  
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Figure 7.   Nanocrystal Size increase upon dilution at room temperature. A) Nanocrystals 
(1:5 w/w PTX/F127). B) Nanocrystals (1:10 w/w PTX/F127). C) Nanocrystals (1:20 w/w 
PTX/F127). D) Nanocrystals (1:30 w/w PTX/F127).  Data represents mean value for at 
least 20 readings for each sample. 
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Figure 7.   Nanocrystal Size increase upon dilution. A) Nanocrystals (1:5 w/w 
PTX/F127). B) Nanocrystals (1:10 w/w PTX/F127). C) Nanocrystals (1:20 w/w 
PTX/F127). D) Nanocrystals (1:30 w/w PTX/F127).  Data represents mean value for at 
least 20 readings for each sample. 
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Figure 8.  TEM of undiluted samples at the end of dilution-size experiment at room 
temperature. Notice the formation of micelles in samples with higher F127 concentrations.  
A) PTX/F127 (1/5 w/w)  B) PTX/F127 (1/10 w/w)  C) PTX/F127 (1/20 w/w)  D) 
PTX/F127 (1/30 w/w). 
 
 
 
      
B)A) 
         
C)  D)
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Figure 9.  Size increase of nanocrystals with high F127 concentration upon dilution.  In 
nanocrystals prepared with high concentration of F127, there was micelle formation in 
solution and formation of hemi-micelles on nanocrystal surface.  These low affinity 
hemi-micelles readily left the surface upon dilution, leading to crystal growth and 
aggregation.  
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Figure 10.  Nanocrystal (1:5 w/w PTX/F127) size increase upon dilution at 37 oC.  Data 
represents mean value for at least 20 readings for each sample. 
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Figure 11.  Re-nanonization by the “Incubation-Sonication” procedure.  After 37 oC 
incubation long crystals were formed due to thermal induced aggregation.  Sonication 
was used to break down long crystals into small nanocrystals again.  After 37 oC 
incubation for the second time, no regrowth in length was observed for these small 
nanocrystals.  
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Figure 12.  Nanocrystal TEM pictures after Incubation-Sonication procedure. A) Break 
down of long crystals into nanocrystals by sonication for 15 min after 2 h 37 oC 
incubation. Measured size by ZetaSizer 139 nm. B) No observed regrowth into long 
crystals by incubating again at 37 oC incubation for 2 hours. Measured Size by ZetaSizer 
163 nm.   
 
 
   
A) 
 
   
B) 
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Figure 13.  Cytotoxicity of Nanocrystals after “Incubation-Sonication” procedure 
1) before 2 hr 37 oC incubation, 2) after 2 hr 37 oC incubation, 3) after 2 hr 37 oC 
incubation then sonication, 4) after 2 hr 37 oC incubation then sonication then 2 hr 37 oC 
incubation again.  Each data represents the mean ± standard deviation (n = 8). 
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Figure 14.  Extraction procedures of PTX with addition of acetonitrile.  Acetonitrile was 
added to dissolve the nanocrystal structure prior to the extraction with tert-butyl methyl 
ether (TBME)  
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Figure 15.  Plasma and Organs PTX Extraction Standard Curves.  The best-fit equations 
to the data points are shown below the graph with y representing PTX amounts (μg) and 
x representing Ratio (PTX/Internal standard). 
 
 
 
Plasma y=0.594x-0.1081 Lung y=0.5516x-0.3605 
Liver y=0.1695x-0.088 Kidney y=0.5335x-0.3405 
Spleen y=0.677x-0.9986 Heart y=0.5354x-0.0348 
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Figure 16.  Nanocrystals biodistribution in mice plasma and organs 1 h post injection.  
Each data represents the mean ± standard deviation (n = 5). 
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